This announcement is a separate document:
邁博藥業-B：內幕消息公告國家藥品監督管理局批准核心產品CMAB009 恩立妥（西妥昔單抗 BETA 注射液）的上市註冊申請(NDA)
MABPHARM-B: INSIDE INFORMATION ANNOUNCEMENTAPPROVAL FROM THE NATIONAL MEDICAL PRODUCTSADMINISTRATION ON THE NEW DRUG APPLICATION (NDA)OF OUR CORE PRODUCT, CMAB009 (CETUXIMAB BETA INJECTION)
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.